Change in grip strength in trans people and its association with lean body mass and bone density by Scharff, Miranda et al.
8:7 1020–1028M Scharff, C M Wiepjes 
et al.
Grip strength change in trans 
people
RESEARCH
Change in grip strength in trans people and  
its association with lean body mass and  
bone density
Miranda Scharff1,*, Chantal Maria Wiepjes1,*, Maartje Klaver1, Thomas Schreiner2, Guy T’Sjoen3 and  
Martin den Heijer1
1Department of Endocrinology and Center of Expertise on Gender Dysphoria, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, 
the Netherlands
2Department of Endocrinology, Oslo University Hospital, Oslo, Norway
3Department of Endocrinology & Center for Sexology and Gender, Ghent University Hospital, Ghent, Belgium
Correspondence should be addressed to M den Heijer: m.denheijer@amsterdamumc.nl
*(M Scharff and C M Wiepjes contributed equally to this work)
Abstract
Objective: Gender-affirming hormonal treatment (HT) in trans people changes physical 
appearance. Muscle mass and strength are important aspects of physical appearance, 
but few data exist on the effect of HT on grip strength and muscle mass. This study 
aimed to investigate the change in grip strength in trans people during the first year of 
HT and to study the possible determinants of this change and the associations between 
changes in grip strength, lean body mass and bone mineral density (BMD).
Design and methods: A multicenter, prospective study was performed, including 249 
transwomen and 278 transmen. Grip strength, lean body mass and BMD were measured 
at baseline and after 1 year.
Results: After 1 year of HT, grip strength decreased with −1.8 kg (95% CI −2.6; −1.0) in 
transwomen and increased with +6.1 kg (95% CI +5.5; +6.7) in transmen. No differences 
in grip strength change was found between age groups, BMI groups, hormonal 
administration routes or hormone concentrations. In transmen, increase in grip strength 
was associated with increase in lean body mass (per kg increase in grip strength: 
+0.010 kg, 95% CI +0.003; +0.017), while this was not found in transwomen (per kg 
increase in grip strength: +0.004 kg, 95% CI −0.000; +0.009). Change in grip strength was 
not associated with change in BMD in transwomen and transmen.
Conclusions: After 1 year of HT, grip strength decreased in transwomen, and increased in 
transmen. In transmen only, change in grip strength was associated with change in lean 
body mass.
Introduction
According to the DSM criteria, gender dysphoria (GD) is 
defined as the incongruence between a person’s assigned 
sex at birth and the experienced gender (1). GD often has 
a strong impact on the person’s psychological wellbeing. 
Therefore, most trans people prefer treatment to change 
physical appearance, for example gender-affirming 
hormonal treatment (HT) with or without gender-
affirming surgery.
Grip strength and muscle mass are good indications 
of the masculinity of the body. A decrease in grip 
strength and muscle mass could lead to a more feminine 
body for transwomen (male-to-female trans people), 
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while an increase in grip strength and muscle mass 
indicates a more masculine body for transmen (female-
to-male trans people). Besides the importance of physical 
appearance, a change in grip strength and muscle mass 
also might be important in the prevention of sarcopenia 
(the age-related loss of muscle mass) (2) and dynapenia 
(the age-related loss of muscle strength) (3).
Earlier studies on effects of HT in trans people focused 
on bone mineral density (BMD) and body composition. 
These studies found an increase in lean body mass in 
transmen and a decrease in lean body mass in transwomen 
(4, 5). BMD increased in both transwomen and transmen 
(6). A study in cis gender people found grip strength to be 
a predictor of bone mass (7). Possibly, a change in BMD in 
trans people is associated with a change in grip strength. 
Some studies described the change in grip strength (8, 
9); however, sample sizes of these studies were small 
and possible influences on these changes, for example 
age, BMI, administration routes of HT and sex hormone 
concentrations during HT, have not been studied.
The aim of this study is to investigate the time course 
of change in grip strength in trans people in the first year 
of HT, to study possible determinants of this change and 
to study the reciprocal associations between changes in 
grip strength, lean body mass (as an approximation of 
muscle mass) and BMD.
Materials and methods
Study design and study population
This study is part of the European Network for the 
Investigation of Gender Incongruence (ENIGI) study, a 
multicenter prospective cohort study, including treatment 
centers in Amsterdam, Ghent, Oslo and Florence using the 
same treatment protocol. The study design is published 
previously (10, 11) and the study is registered at https://
clinicaltrials.gov/ct2/show/NCT01072825. In short, 
people were included from 2010 until April 2016. The 
included people were 18 years and older and gave informed 
consent. People could participate in this study when they 
started with HT, if they did not use gender-affirming 
hormones before the start of HT, and if they spoke the 
native language. During the first year of treatment, the 
people were seen every 3 months. For the current study, 
only data from Amsterdam, Ghent and Oslo were analyzed, 
as grip strength was not assessed in Florence. People were 
included if their grip strength was measured at baseline 
and after 12 months. For the analyses on lean body mass 
and BMD, people were included if a dual-energy X-ray 
absorptiometry (DXA) was performed at baseline (range 
4  months before to 4  months after baseline) and after 
12 months (range 10–14 months) of HT. People from Oslo 
were excluded from the analyses on lean body mass and 
BMD, because a different type of DXA scanner was used 
(Oslo: Lunar (GE Lunar, Madison, WI, USA); Amsterdam 
and Ghent: Hologic Discovery A (Hologic Inc, Bedford, 
MA, USA)). In total, 1017 participants were included 
in the overall study. After exclusions due to unknown 
grip strength values at baseline or 12 months (n = 60), a 
follow-up of less than 1 year (n = 363) or lost to follow-up 
(n = 57), a total of 249 transwomen and 278 transmen 
were included in our analyses (Fig. 1).
Transwomen were treated with the anti-androgen 
cyproterone acetate (CPA) 50 mg daily, in combination 
with 2–4 mg oral estradiol valerate a day or 100 µg/24 h 
estradiol patch twice a week. People older than 40 years 
were advised to be treated with transdermal estrogens, 
because of thrombosis risk (12). Transmen were treated with 
testosterone. They could choose between testosterone gel 
(50 mg daily), testosterone esters (250 mg intramuscular 
every 2–3  weeks) or testosterone undecanoate (1000 mg 
intramuscular every 12 weeks).
The Medical Ethics Review Committee of Ghent 
approved the study protocol. Local Ethical Review 
Committees approved participations in the other centers.
Clinical data collection
Grip strength was measured in kilograms (kg), using 
an adjustable hand-held standard grip device, a Jamar 
Dynamometer (10, 13). The grip strength of the dominant 
hand was measured twice and the highest value was 
noted. These measurements were performed at baseline 
and after 3 months, 6 months, 9 months and 12 months 
of HT. However, from Oslo only data at baseline and after 
12 months were available.
Body weight and height were measured at every visit. 
People were measured without shoes and in light indoor 
clothes. BMI was calculated by weight divided by the 
square of body height.
DXA
A whole-body DXA was performed to measure lean 
body mass of the arms and the legs. Outcomes of body 
composition were determined using manufacturer-
supplied algorithms. The specific arm and leg regions 
were defined with software from Hologic.
Absolute BMD values were obtained for lumbar 
spine (L1–L4, LS), total hip (TH) and femoral neck (FN). 
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The same type of DXA device was used in Amsterdam and 
Ghent (Hologic Discovery A, Hologic Inc., MA, USA) and 
software version 13.5.3 was used.
Laboratory measurements
Venous blood samples were obtained in the morning at 
baseline, after 3 months of HT and after 12 months of HT. 
As the results were also used during clinical care, assays 
with higher quality were implemented when they were 
available. In order to compare the new and old values 
likewise, conversion formulas were generated by the 
endocrine laboratory.
In Oslo, testosterone and estradiol were determined 
using a competitive immunoassay (ECLIA, Roche 
Diagnostic) with a lower limit of quantitation (LOQ) of 
0.1 nmol/L (2.6 ng/dL) and 18.4 pmol/L (5.0 pg/mL), and a 
coefficient of variation (CV) of 5 and 7%, respectively. In 
Ghent, an E170 Modular (E2 Gen II, Roche Diagnostics) 
was used for testosterone (LOQ 0.4 nmol/L (11.5 ng/dL), 
CV 2.6%) and estradiol (LOQ 92 pmol/L (25.1 pg/mL), 
CV 3.2%). For estradiol, it was updated in March 2015 to 
an E170 Modular (E2 Gen III, Roche Diagnostics) with a 
conversion formula of Gen III = 6.687940 + 0.834495 × Gen 
II. In Amsterdam, estradiol was measured using a 
competitive immunoassay (Delfia, PerkinElmer, Wallac 
Oy, Turku, Finland) with a LOQ of 20 pmol/L (5.4 pg/mL) 
and a CV of <13% until July 2014. Thereafter, an LC-MS/MS 
(VUmc, Amsterdam, the Netherlands; LOQ 20 pmol/L 
(5.4 pg/mL), CV <7%) was used, with a conversion formula 
of LC-MS/MS = 1.60 × Delfia-29. Testosterone was measured 
using a radioimmunoassay (RIA, Coat-A-Count, Siemens, 
Los Angeles, CA, USA; LOQ 1 nmol/L (28.8 ng/dL), CV 
<10%) until January 2013. After that, it was measured 
using a competitive immunoassay (Gen III, Architect, 
Abbott, Abbott Park, IL, USA) with a LOQ of 0.1 nmol/L 
(2.9 ng/dL) and a CV <10%. Two conversion formulas 
were generated: <8 nmol/L: Architect = 1.1 × RIA + 0.2; 
>8 nmol/L: Architect = 1.34 × RIA-1.65.
Statistical analyses
Results are presented as mean with standard deviation (s.d.) 
in case of normal distribution, or median with interquartile 
range (IQR) for non-normally distributed data, and 
percentages. In case of non-normally distributed data, a 
log transformation was performed before further analyses.
To examine the course of the change in grip strength 
during the first year, linear mixed model analyses were 
performed. The influence of age, differences in BMI, 
different administration routes of HT and serum hormone 
concentrations, were analyzed. Age was divided into 
groups (<25  years, 25–40  years, ≥40  years), to stratify 
for accrual of grip strength, peak grip strength and 
Figure 1
Inclusion flowchart.
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age-related decrease of grip strength. BMI was defined as 
underweight (<18.5 kg/m2), normal weight (18.5–25 kg/m2) 
and overweight (≥25 kg/m2). For analyses between 
differences in the administration route of HT, people who 
used the same administration route for at least 9 months 
were included. Mean concentrations of estradiol and 
testosterone during HT were calculated by averaging the 
results of the measurements after 3 and after 12 months 
of HT. As different assays were used in the centers to 
determine estradiol and testosterone and no conversion 
formulas between the centers were available, it was 
not possible to analyze the estradiol and testosterone 
concentrations as absolute values. Therefore, center-
specific tertiles were created for estradiol and testosterone 
and were thereafter analyzed together. The center-specific 
mean estradiol concentrations in transwomen were first 
tertile 122 pmol/L (33 pg/mL, Amsterdam), 159 pmol/L 
(43 pg/mL, Ghent) and 167 pmol/L (46 pg/mL, Oslo); 
second tertile 233 pmol/L (63 pg/mL, Amsterdam), 
248 pmol/L (68 pg/mL, Ghent) and 317 pmol/L (83 pg/mL, 
Oslo); and third tertile 405 pmol/L (110 pg/mL, Amsterdam), 
572 pmol/L (156 pg/mL, Ghent) and 398 pmol/L 
(108 pg/mL, Oslo). The center-specific mean testosterone 
concentrations for transmen were first tertile: 16 nmol/L 
(461 ng/dL, Amsterdam), 10 nmol/L (288 ng/dL, Ghent) 
and 15 nmol/L (432 ng/dL, Oslo); second tertile: 28 nmol/L 
(806 ng/dL, Amsterdam), 16 nmol/L (461 ng/dL, Ghent) 
and 21 nmol/L (605 ng/dL, Oslo); and third tertile: 
54 nmol/L (1555 ng/dL, Amsterdam), 24 nmol/L (691 ng/dL, 
Ghent) and 33 nmol/L (950 ng/dL, Oslo).
The average of the right and left arm was calculated 
for the analyses on the lean body mass of the arms, 
and the average of the right and left leg was calculated 
to analyze the lean body mass of the legs. To evaluate 
the change of grip strength, lean body mass, BMD, and 
serum creatinine after 1 year, the absolute and percentage 
difference between the baseline values and the values 
after 12  months were calculated. As these were normal 
distributed variables, linear regression analyses were 
performed to calculate the mean and 95% CI.
To study the association between changes in grip 
strength and changes in lean body mass, BMD or creatinine 
concentrations, linear regression analyses were performed.
All analyses were performed separately for transwomen 
and transmen. Data were analyzed using STATA Statistical 
Software (Statacorp, version 15.1). P values <0.050 were 
considered statistically significant.
Results
Characteristics
The characteristics are shown in Table 1. No differences 
were found between included and excluded people in 
Table 1 Characteristics of the study population.
Transwomen (n = 249) Transmen (n = 278)
Baseline During HT Baseline During HT
Age, years 28 (23–40) 23 (20–30)
BMI, kg/m2 23.8 (4.5) 24.5 (4.4) 25.5 (5.6) 25.9 (4.8)
Smoking (% yes) 24.7 14.7 29.9 19.9
Alcohol (% yes) 44.8 44.6 55.3 55.8
Grip strength (kg) 41.8 (8.9) 40.0 (8.9) 33.1 (6.5) 39.2 (6.8)
Creatinine (µmol/L) 78.5 (10.8) 73.1 (10.6) 66.0 (9.0) 77.4 (10.6)
Hormone administration routea
 Estradiol oral – 134 – –
 Estradiol transdermal – 86 – –
 Testosterone gel – – – 52
 Testosterone undecanoate i.m. – – – 130
 Testosterone esters i.m. – – – 81
Estradiol concentrations, pmol/L 
 Amsterdam 105 (83–131) 225 (141–329) 142 (59–371) 180 (138–242)
 Ghent 109 (88–130) 246 (181–342) 166 (116–431) 134 (113–169)
 Oslo 120 (100–140) 257 (195–325) 280 (180–480) 168 (140–210)
Testosterone concentrations, nmol/L
 Amsterdam 18.5 (14.0–23.0) 0.8 (0.6–0.9) 1.3 (1.0–1.7) 27.8 (19.5–39.0)
 Ghent 17.9 (13.5–21.5) 0.7 (0.5–1.1) 1.0 (0.7–1.3) 16.3 (11.2–21.1)
 Oslo 18.1 (12.2–20.4) 0.4 (0.4–0.6) 1.0 (0.8–1.3) 21.4 (16.7–28.5)
Data are presented as median with inter quartile range, mean with standard deviation, percentages or absolute numbers.
aOnly in people who used the same hormone administration route for >75% of the follow-up time.
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International License.https://doi.org/10.1530/EC-19-0196
https://ec.bioscientifica.com © 2019 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 03/09/2020 01:39:52PM
via Universiteit Gent/Uzgent, Universiteit Ghent, Universitair Ziekenhuis and Universiteitsbibliotheek Gent
M Scharff, C M Wiepjes 
et al.
Grip strength change in trans 
people
1024
PB–9
8:7
baseline grip strength, age, BMI, estradiol concentrations, 
testosterone concentrations or smoking habits 
(Supplementary Table  1, see section on supplementary 
data given at the end of this article).
For the analyses on lean body mass, 171 transwomen 
and 154 transmen were included. For these analyses, 
excluded transwomen were younger (median age 26 years, 
IQR 21–34) than included transwomen (median age 
31  years, IQR 23–42). Excluded transmen were younger 
(median age 22  years, IQR 19–25) and had a lower BMI 
(mean 24.3 kg/m2, s.d. 5.2) than included transmen (median 
age 28 years, IQR 20–33, and mean BMI 26.0 kg/m2, s.d. 5.5). 
No differences were found between included and excluded 
people in baseline grip strength, estradiol concentrations, 
testosterone concentrations or smoking habits.
For the analyses on LS BMD, 207 transwomen and 229 
transmen were included. For TH and FN, 206 transwomen 
and 216 transmen were included. No differences were 
found between included and excluded transwomen. 
Excluded transmen were younger (median age 21 years, 
IQR 19–25) than included transmen (median age 24 years, 
IQR 21–31).
Grip strength
In transwomen, grip strength decreased with −1.8 kg 
(95% CI −2.6; −1.0), while in transmen, grip strength 
increased with +6.1 kg (95% CI +5.5; +6.7). The course of 
the grip strength change over time is shown in Fig. 2. For 
transwomen, 66% of the decrease in grip strength (−1.2 kg) 
occurred in the last 3  months, while in transmen 49% 
of the increase (+3.0 kg) occurred in the first 3 months. 
Change in grip strength did not vary between different 
age groups (Fig. 3A), different BMI groups (Fig. 3B) and 
different administration routes of HT (Fig. 3C), for both 
transwomen and transmen. Change in grip strength did 
not vary between different hormone concentrations, for 
either transwomen or transmen (Fig.  3D). No analyses 
on testosterone concentrations in transwomen could be 
performed, as testosterone was suppressed (<2 nmol/L, 
<58 ng/dL) in the majority of the transwomen (94%).
Grip strength in relation to lean body mass
As reported previously in this study population (4), a 
decrease in lean body mass was observed in transwomen 
and an increase in lean body mass was observed in 
transmen during the first year of HT.
Associations of change in grip strength with change in 
lean body mass are presented in Table 2. In transwomen, 
no associations between change in grip strength and 
change in arm or leg lean body mass was seen. In 
transmen, increase in grip strength was associated with 
an increase in arm lean body mass (per kg increase in grip 
strength: +0.010 kg, 95% CI +0.003; +0.017), but not with 
change in leg lean body mass.
Grip strength in relation to BMD
As reported previously in this study population (6), 
increases in LS BMD, TH BMD and FN BMD were observed 
in transwomen, and increases in LS BMD and TH BMD, 
but not FN BMD, were observed in transmen during the 
first year of HT.
The associations of change in grip strength 
with change in BMD are shown in Table  2. 
Figure 2
Change in grip strength during the first 12 months of gender-affirming 
hormonal treatment in transwomen and transmen. Data are presented as 
means with 95% CI. The 25th and 75th percentiles of the reference 
populations are shown with dashed lines. For transwomen the  
25th percentile is 25 kg and the 75th percentile is 31 kg. For transmen  
the 25th percentile is 36 kg and the 75th percentile is 50 kg (18).
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Figure 3
Differences in change in grip strength for age 
groups, BMI groups, routes of hormonal 
administration, estradiol concentrations and 
testosterone concentrations. Data are presented 
as means with 95% CIs. Reference values (25th 
and 75th percentile) are based on the mean age 
of this population. For transwomen the 25th 
percentile is 25 kg and the 75th percentile is 31 kg. 
For transmen the 25th percentile is 36 kg and the 
75th percentile is 50 kg (18). (A) Grip strength 
change over 12 months between age, adjusted for 
administration route. (B) Grip strength change 
over 12 months between BMI groups. (C) Grip 
strength change over 12 months between 
different administration routes, adjusted for age. 
(D) Grip strength change over 12 months between 
different hormone concentrations.
Table 2 Associations between change in grip strength (per kg increase) and lean body mass, bone mineral density and 
creatinine, separately for transwomen and transmen.
Transwomen Transmen
Mean change (95% CI) P value Mean change (95% CI) P value
Lean body mass
 Arm +0.004 kg (−0.000; +0.009) 0.079 +0.010 kg (+0.003; +0.017) 0.003
 Leg +0.009 kg (−0.003; +0.021) 0.161 +0.014 kg (−0.002; +0.030) 0.078
Bone mineral density
 Lumbar spine +0.02% (−0.05; +0.10) 0.556 +0.01% (−0.08; +0.09) 0.900
 Total hip +0.05% (−0.01; +0.10) 0.112 −0.02% (−0.09; +0.05) 0.630
 Femoral neck +0.05% (−0.03; +0.12) 0.201 +0.04% (−0.06; +0.15) 0.401
Creatinine −0.1 µmol/L (−0.2; +0.1)a 0.535 +0.2 µmol/L (+0.0; +0.4) 0.035
aData shown is per kg decrease in grip strength.
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Change in grip strength was not associated with change 
in BMD in both transwomen and transmen.
Grip strength in relation to creatinine
Serum creatinine concentrations decreased with 
−5.0 µmol/L (95% CI −6.2; −3.8) in transwomen and 
increased with +11.1 µmol/L (95% CI +10.1; +12.2) in 
transmen. The associations of change in grip strength 
with change in creatinine are described in Table  2. In 
transmen, the increase in creatinine was associated 
with an increase in grip strength (per kg increase in grip 
strength: +0.2 µmol/L, 95% CI +0.0; +0.4). In transwomen, 
a decrease in creatinine tended to be associated with a 
decrease in grip strength (per kg decrease in grip strength: 
−0.1 µmol/L, 95% CI −0.2; +0.1).
Discussion
In transwomen, a decrease in grip strength after 1  year 
of HT was found, while in transmen, an increase in grip 
strength after 1 year of HT was found. These changes were 
also found in the serum creatinine concentrations. Grip 
strength change did not vary between age groups, BMI 
groups, administration routes and different hormone 
concentrations, for neither transwomen nor transmen. 
Change in grip strength was associated with change in 
lean body mass in transmen but not in transwomen. 
Change in grip strength was not associated with a change 
in BMD.
In our study, transwomen decreased in grip strength, 
possibly due to the lack of testosterone. This is in 
agreement with a study in young men using gonadotropin-
releasing hormone agonists, which found that muscle 
mass decreased by approximately 1 kg after 10 weeks (14). 
The finding of an increase in grip strength in transmen 
is consistent with results from studies about testosterone 
replacement in hypogonadal men (15). Testosterone 
has an effect on myoblast proliferation and myoblast 
differentiation, and testosterone increases the number 
of satellite cells, which promotes protein synthesis of 
muscle mass (16). Thus, testosterone plays an important 
role in muscle mass and muscle strength. Accordingly, 
testosterone is not only important for muscle in men, but 
also for muscle in women. This is among others important 
for the prevention of dynapenia in older people.
The largest decrease in grip strength for transwomen 
took place in the last 3 months of HT, while the largest 
change for transmen took place in the first 3  months. 
The change in transmen is in line with a randomized 
controlled trial that shows an increase in strength in the 
first 6 months, after the use of testosterone in healthy men 
≥60  years old (17). Interestingly, the time difference of 
the slow loss of grip strength in transwomen and the fast 
increase in transmen is opposite of what is observed for 
strength with training and detraining. It might possibly 
take longer for muscles to decrease in proteins due to lack 
of testosterone, than it is to increase due to administration 
of testosterone. However, to fully understand the 
difference, more research is necessary. After 12 months, 
the median grip strength of transwomen still falls into the 
95th percentile for age-matched females. The median grip 
strength of transmen after 12 months falls into the 25th 
percentile of age-matched males (18). Thus, transwomen 
are still stronger than average females and transmen are 
still weaker than average males. However, as this study is a 
follow-up of 12 months, transwomen and transmen might 
attain a grip strength value closer to the reference values 
of, respectively, females and males after a longer duration 
of HT. No difference was found for grip strength change 
between age groups, BMI groups and administration routes. 
A larger decrease in transwomen and a smaller increase in 
transmen was expected at age ≥40 years, because of the 
age-related decrease of grip strength in combination with 
the lack of testosterone. However, our study population 
of ≥40  years was not very old (mean age 49  years for 
transwomen and 47  years for transmen). Furthermore, 
our study suggests that change in grip strength was not 
related to mean serum hormone concentrations during 
the first year of HT. This finding is line with a study on 
endocrine determinants in sarcopenia in 518 men aged 
40–79  years, which found no association between total 
and bioavailable testosterone and the annual change in 
grip strength in men, after a follow-up of 4.3 years (19). The 
finding that concentrations of testosterone and estradiol 
were not associated with the change in grip strength can 
be used to inform trans people that a higher dosage does 
not lead to a larger increase or decrease in grip strength. 
Also, because no relationship was found between change 
in grip strength and administration routes, trans people 
can make a more well-informed decision when choosing 
between administration routes.
In transwomen, no association was found between 
change in lean body mass and change in grip strength, 
while it was only weakly associated in transmen. This 
is in contrast to a large cross-sectional and longitudinal 
perspective study of 847 participants aged 20–100 years, 
which found a strong correlation between grip strength 
and lean body mass (20). However, this correlation was 
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age dependent, and it was the strongest at 60 years old. 
People younger than 60  years appeared to be stronger 
than predicted with muscle mass and people older 
than 60 years appeared to be weaker. They also showed 
a stronger correlation between age and grip strength 
compared to age and muscle mass. Our population has 
a mean age of 25 years, this is significantly younger than 
60 years, thus the correlation might be lower. Furthermore, 
change in grip strength was not associated to change in 
BMD. Therefore, change in BMD cannot be predicted by 
change in grip strength.
This is a large, multicenter, prospective study. 
Standardized measurements were used to measure grip 
strength, and there is a widespread age range. To our 
knowledge, this is the first study that describes the 
change in grip strength over the course of a year and that 
examines possible influences on this change. However, 
our study also had some limitations. First, data about 
physical activity were only available in smaller subgroup 
of the study population and was therefore not analyzed. 
Therefore, we could miss data that can partially explain 
the change in grip strength. However, in previous studies, 
no change in physical activity was found in transwomen 
(8) and transmen (9) during the first year of HT. Second, 
possibly a true impact of testosterone concentrations 
on grip strength cannot be detected, since circulating 
testosterone concentrations were evaluated, instead of 
available testosterone in muscle cells (21). In addition, the 
laboratory measurements were performed differently at the 
study centers and changed in two sites during follow-up. 
Although conversion formulas were generated and tertiles 
were used instead of absolute values, it might be that the 
variability in hormone concentrations affected the results. 
Lastly, it is questionable whether a decrease in grip strength 
in transwomen of almost 2 kg is clinically relevant. 
Nonetheless, transwomen possibly feel more feminine due 
to the decrease in muscle mass (22, 23). One study reported 
on the desired effects of HT in transwomen in Indonesia, 
including reduced muscle mass (23). A study in associations 
among masculinity, strength and attractiveness shows a 
positive correlation between masculinity and grip strength, 
and a negative correlation between masculinity and 
attractiveness in young women (24). This might indicate 
that a decrease in grip strength in women could influence 
the feeling of attractiveness. However, this may be 
dissimilar in transwomen. A questionnaire for transwomen 
and transmen would be of interest to investigate a possible 
satisfaction with the change in grip strength.
In conclusion, grip strength decreases in transwomen 
and increases in transmen, after 12  months of HT. 
This is interesting for the prevention of sarcopenia and 
dynapenia, since testosterone has a positive effect on 
muscle mass and grip strength. In addition, knowing 
the effects of HT on grip strength, its association with 
hormone concentrations and hormonal administration 
routes, and its relation with change in muscle mass and 
BMD, can help care providers and trans people with 
their expectations of HT. For further research, it would 
be interesting to evaluate the subjective satisfaction 
related to changes in grip strength and to evaluate the 
change of grip strength after a longer follow-up to see if 
the grip strength will reach the grip strength reference 
values for women or men, for transwomen and transmen, 
respectively.
Supplementary data
This is linked to the online version of the paper at https://doi.org/10.1530/
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